Retatrutide for the treatment of obesity, obstructive sleep apnea and the TRIUMPH clinical development program
GLP-1RAs, originally developed for glycemic control, have shown neuroprotective properties in many preclinical studies
In July 2024 , Genentech , a member of the Roche Group announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity
At Moriarty Injury Lawyer, we are here to help you understand your rights and explore the possibility of recovering compensation for your suffering
Excluded are defendants, the company's officers and directors at all relevant times, their immediate families, legal representatives, heirs, successors or assigns, and any entity in which defendants have or had a controlling interest
Clinical studies are scarce, highlighting the need for further research to assess bone quality and long-term skeletal outcomes in individuals using GLP-1s